Targeted Gene Delivery by Tropism-Modified Adenoviral Vectors

Joanne T. Douglas, Buck E. Rogers, Maryland E. Rosenfeld, Sharon I. Michael, Meizhen Feng, David T. Curiel

Research output: Contribution to journalArticle

378 Scopus citations

Abstract

The utility of adenoviral vectors for gene therapy is currently limited due, in part, to the widespread distribution of the cellular receptor for the adenovirus fiber that precludes the targeting of specific cell types. In order to develop a targeted adenovirus, it is therefore necessary both to ablate endogenous viral tropism and to introduce novel tropism. We hypothesized that these two goals could be achieved by employing a neutralizing anti-fiber antibody, or antibody fragment, chemically conjugated to a cell-specific ligand. To test this concept, we chose to target the folate receptor, which is overexpressed on the surface of a variety of malignant cells. Therefore, we conjugated folate to the neutralizing Fab fragment of an anti-fiber monoclonal antibody. This Fab-folate conjugate was complexed with an adenoviral vector carrying the luciferase reporter gene and was shown to redirect adenoviral infection of target cells via the folate receptor at a high efficiency. Furthermore, when complexed with an adenoviral vector carrying the gene for herpes simplex virus thymidine kinase, the Fab-folate conjugate mediated the specific killing of cells that overexpress the folate receptor. This work thus represents the first demonstration of the retargeting of a recombinant adenoviral vector via a non-adenoviral cellular receptor.

Original languageEnglish
Pages (from-to)1574-1578
Number of pages5
JournalNature Biotechnology
Volume14
Issue number11
DOIs
StatePublished - Nov 1996
Externally publishedYes

Keywords

  • Gene therapy
  • Targeted adenovirus

Fingerprint Dive into the research topics of 'Targeted Gene Delivery by Tropism-Modified Adenoviral Vectors'. Together they form a unique fingerprint.

  • Cite this